Wu D, Li J, Xu D et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024 Mar 12;83(4):475-487. PMID: 38129117
Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16;2:16039. PMID: 27306639.
Samy E, Wax S, Huard B et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017 Jan 2;36(1):3-19. PMID: 28215100.
Parodis I, Long X, Karlsson MCI et al. B Cell Tolerance and Targeted Therapies in SLE. J Clin Med. 2023 Sep 28;12(19):6268. PMID: 37834911.
Huard B, Tran NL, Benkhoucha M, et al. Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One. 2012;7(2):e31837. PMID: 22355399.
Cai J, Gao D, Liu D, et al. Telitacicept for autoimmune nephropathy. Front Immunol. 2023 Jun 5;14:1169084. PMID: 37342346.
Neusser MA, Lindenmeyer MT, Edenhofer I, et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol. 2011 Jan;24(1):98-107. PMID: 20890272.
A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects. NCT 04235933.
Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023 Feb;75(2):242-252 PMID: 36369798.
Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018 Mar;77(3):355-363.. PMID: 29295825.
Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019 Dec;1(4):e208-e219. PMID: 38229377.
Zeng L, Yang K, Wu Y, et al. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun. 2024 Aug 14;148:103291. PMID: 39146891.
Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012 Feb 7;14(1):R33. PMID: 22325903
Felten R, Scherlinger M, Mertz P, et al. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine. 2023 Mar;90(2):105523. PMID: 36623799.
Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006-15. PMID24951103
